Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Antitumor activity of KEYNOTE158 and CheckMate 358. | Download ...
CheckMate 358: análise da combinação de nivolumabe (NIVO) e ipilumabe ...
CHECKMATE 358: immunotherapy in combination points to paradigm shift in ...
CheckMate 8HW Trial at ASCO 2025: Nivolumab Plus Ipilimumab Sets New ...
(PDF) Checkmate 274 trial: Is Nivolumab the new standard in adjuvant ...
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 ...
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients ...
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and ...
CheckMate 451——Nivolumab和Ipilimumab作为广泛期小细胞肺癌的维持治疗 - 知乎
| Comparisons between the CheckMate 227 trial and simulation, overall ...
Thirty-month follow-up of the phase III CheckMate 214 trial of first ...
CheckMate 017/057的五年生存结果：Nivolumab在二线非小细胞肺癌治疗中优于多西他赛 - 精选 - 阳光肺科
CheckMate 171: A phase 2 trial of nivolumab in patients with previously ...
(PDF) Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate ...
CheckMate 358:Имунотерапия при рецидивирал или метастатичен карцином на ...
(PDF) CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline ...
Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO ...
Three-year follow-up and patient-reported outcomes from CheckMate 078 ...
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell ...
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV ...
Nivolumab with or without ipilimumab in patients with recurrent or ...
2022 ESMO丨CheckMate 358研究：NIVO+IPI可使R/M宫颈癌患者肿瘤持久消退 - 知乎
(PDF) Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell ...
(PDF) Neoadjuvant nivolumab for patients with resectable HPV-positive ...
(PDF) Immunotherapy for Uterine Cervical Cancer Using Checkpoint ...
ESMO 2022: Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI ...
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic ...
Merkel Cell Carcinoma: From Diagnosis to Treatment (webinar) | PPTX
Baseline Patient and Tumor Characteristics | Download Scientific Diagram
An open-label, multicohort, phase I/II study to evaluate nivolumab in ...
Nivolumab plus chemotherapy in first-line metastatic non-small-cell ...
Characterization of Patients with Lymph Node Only Metastatic Urothelial ...
Frontiers | Nivolumab adjuvant therapy for esophageal cancer: a review ...
Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus ...
Nivolumab in metastatic urothelial carcinoma after platinum therapy ...
Tumor Responses According to RECIST, version 1.1 | Download Scientific ...
Nivolumab in Patients With Advanced or Metastatic Malignancies ...
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma ...
Table 1 from Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma ...
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus ...
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory ...
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After ...
Comparative effectiveness of nivolumab versus clinical practice for ...
Table 1 from Nivolumab Versus Docetaxel in Previously Treated Patients ...
Nivolumab for muscle-invasive urothelial cancer
Adjuvant nivolumab versus placebo for high-risk muscle-invasive ...
Health-related Quality of Life with Adjuvant Nivolumab After Radical ...
(PDF) Safety and Efficacy of Nivolumab in Patients With Advanced Clear ...
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma ...
Nivolumab in Patients With Advanced Hepatocellular Carcinoma: the ...
(PDF) Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma ...
Figure 2 from Nivolumab in patients with advanced hepatocellular ...
Nivolumab versus sorafenib in advanced hepatocellular carcinoma ...
Updated Results From a Phase I Study of Nivolumab in Combination With ...
How to Integrate Perioperative Immunotherapy Into Multimodal Treatment ...
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes ...
(PDF) CheckMate-032 Study: Efficacy and Safety of Nivolumab and ...
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in ...
Dual Checkpoint Blockade in Merkel Cell Carcinoma: Lessons from ...
宫颈癌已获批上市创新药进展汇总丨单抗、双抗、ADC、组合抗体 宫颈癌2030年是《加速消除宫颈癌全球战略》和《健康中国2030》纲要的共同关键 ...
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell ...
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab ...
Table 1 from Adjuvant nivolumab versus placebo following radical ...
新辅助药Nivolumab用于可切除的默克尔细胞癌 - 知乎
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB ...
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With ...
Daniel P. Petrylak | New Targets for Advanced Bladder Cancer
Journal of Clinical Images and Medical Case Reports
CCO_LungIO_Downloadble_Slides_1.pptx
00088-3/asset/5db553ea-276f-449a-b2a4-de7c1974ae26/main.assets/gr2.jpg)
30496-X/asset/cd434168-ddeb-40af-8042-70c21826734f/main.assets/gr2_lrg.jpg)
